Drug Trial Radar · NCT07806058
An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IB/II clinical trial designed to evaluate HRS-7172 in combination with antitumor drugs in participants with advanced pancreatic cancer harboring RAS mutations or amplifications. The study process includes a screening period (from signed informed consent to first dose), a treatment period (from first dose to last dose), and a follow-up period (safety and survival follow-up after last dose). A Safety Monitoring Committee (SMC), composed of the principal investigator and sponsor representatives, will be established during the study to review the safety and efficacy data generated. The SMC will make decisions on study-related matters, including but not limited to combination regimen dose exploration, combination regimen selection, efficacy expansion cohort selection, expansion initiation timing, and recommended dose for expansion (RDE). This study aims to evaluate the safety, tolerability, and efficacy of HRS-7172 in combination with other antitumor therapies in participants with advanced or metastatic pancreatic cancer harboring RAS mutations or amplifications.
Conditions
- Pancreatic Cancer
Interventions
HRS-7172 + AG + SHR-1316Drug
HRS-7172 + AG + SHR-1316; low dose
HRS-7172 + AG + SHR-1316;Drug
HRS-7172 + AG + SHR-1316; high dose
HRS-7172 + AG;Drug
HRS-7172 + AG; low/high dose
HRS-7172 + AG + SHR-1316;Drug
HRS-7172 + AG + SHR-1316; low/high dose
HRS-717 + HRS-4642+SHR-1316;Drug
HRS-717 + HRS-4642+SHR-1316; low dose
HRS-717 + HRS-4642+SHR-1316;Drug
HRS-717 + HRS-4642+SHR-1316; high dose
HRS-717 + HRS-4642;Drug
HRS-717 + HRS-4642; low/high dose
HRS-717 + HRS-4642+SHR-1316;Drug
HRS-717 + HRS-4642+SHR-1316; low/high dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- RDE in advanced pancreatic cancer with RAS mutation or amplificationTime frame: From the signing of the informed consent form to the end of the safety follow-up. Estimated to be 2 years
- Incidence and severity of adverse events (AEs) (per NCI-CTCAE V6.0 criteria)Time frame: From the signing of the informed consent form to the end of the safety follow-up. Estimated to be 2 years
- ORR assessed by the investigatorTime frame: From the signing of the informed consent form to the end of the safety follow-up. Estimated to be 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.